Achillion Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ACHN)

$3.43 -0.13 (-3.65 %)
(As of 11/20/2017 01:42 PM ET)
Previous Close$3.56
Today's Range$3.38 - $3.55
52-Week Range$2.95 - $5.66
Volume2.00 million shs
Average Volume1.66 million shs
Market Capitalization$472.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66

About Achillion Pharmaceuticals (NASDAQ:ACHN)

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system. The complement system is part of the human innate immune system. Its clinical compound from its complement inhibitor platform is ACH-4471. ACH-4471 is a potent and specific inhibitor of factor D, which demonstrated complete inhibition of the complement alternative pathway in human healthy volunteers in a Phase I clinical trial. The Company has discovered and advanced multiple compounds into clinical development, including sovaprevir, odalasvir, and ACH-3422 in its hepatitis C virus (HCV) program.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Sector: Healthcare
  • Symbol: NASDAQ:ACHN
  • CUSIP: 00448Q20
  • Web: www.achillion.com
Debt:
  • Current Ratio: 22.66%
  • Quick Ratio: 22.66%
Sales & Book Value:
  • Annual Sales: $15 million
  • Price / Sales: 31.52
  • Book Value: $2.92 per share
  • Price / Book: 1.17
Profitability:
  • Trailing EPS: ($0.49)
  • Net Income: ($61,700,000.00)
  • Return on Equity: -17.84%
  • Return on Assets: -17.21%
Misc:
  • Employees: 81
  • Outstanding Shares: 137,860,000
 

Frequently Asked Questions for Achillion Pharmaceuticals (NASDAQ:ACHN)

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) posted its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.04. During the same period last year, the firm earned ($0.15) earnings per share. View Achillion Pharmaceuticals' Earnings History.

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

6 brokers have issued 1-year price objectives for Achillion Pharmaceuticals' shares. Their forecasts range from $4.00 to $7.00. On average, they expect Achillion Pharmaceuticals' share price to reach $5.50 in the next twelve months. View Analyst Ratings for Achillion Pharmaceuticals.

Who are some of Achillion Pharmaceuticals' key competitors?

Who are Achillion Pharmaceuticals' key executives?

Achillion Pharmaceuticals' management team includes the folowing people:

  • David I. Scheer, Independent Chairman of the Board (Age 64)
  • Milind S. Deshpande Ph.D., President, Chief Executive Officer, Director (Age 60)
  • Mary Kay Fenton CPA, Chief Financial Officer, Executive Vice President (Age 52)
  • Martha E. Manning Esq., , Executive Vice President, General Counsel, Corporate Secretary (Age 62)
  • David Apelian M.D., Ph.D.,, Executive Vice President, Chief Medical Officer (Age 51)
  • Joseph Truitt, Executive Vice President, Chief Commercial Officer (Age 52)
  • Jason S. Fisherman M.D., , Independent Director (Age 60)
  • Gary E. Frashier, Independent Director (Age 80)
  • Kurt C. Graves, Independent Director (Age 49)
  • Michael D. Kishbauch, Independent Director (Age 68)

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Orbimed Advisors LLC (9.54%), RTW Investments LP (5.73%), RTW INVESTMENTS, LP (5.20%), Janus Henderson Group PLC (2.83%), Dimensional Fund Advisors LP (2.39%) and Sarissa Capital Management LP (1.56%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Institutional Ownership Trends for Achillion Pharmaceuticals.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Janus Henderson Group PLC, GSA Capital Partners LLP, OxFORD Asset Management LLP, Orbimed Advisors LLC, Wells Fargo & Company MN and California State Teachers Retirement System. View Insider Buying and Selling for Achillion Pharmaceuticals.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Sarissa Capital Management LP, Dimensional Fund Advisors LP, Artal Group S.A., Candriam Luxembourg S.C.A., Sphera Funds Management LTD., Shell Asset Management Co. and Schwab Charles Investment Management Inc.. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton. View Insider Buying and Selling for Achillion Pharmaceuticals.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Achillion Pharmaceuticals' stock price today?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $3.43.

How big of a company is Achillion Pharmaceuticals?

Achillion Pharmaceuticals has a market capitalization of $472.85 million and generates $15 million in revenue each year. The biopharmaceutical company earns ($61,700,000.00) in net income (profit) each year or ($0.49) on an earnings per share basis. Achillion Pharmaceuticals employs 81 workers across the globe.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 George St, NEW HAVEN, CT 06511-6624, United States. The biopharmaceutical company can be reached via phone at +1-203-6247000.


MarketBeat Community Rating for Achillion Pharmaceuticals (NASDAQ ACHN)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  320 (Vote Outperform)
Underperform Votes:  235 (Vote Underperform)
Total Votes:  555
MarketBeat's community ratings are surveys of what our community members think about Achillion Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Achillion Pharmaceuticals (NASDAQ:ACHN)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 3 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.50 (60.35% upside)

Consensus Price Target History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Price Target History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/17/2017Chardan CapitalReiterated RatingNeutralHighView Rating Details
9/12/2017Ladenburg Thalmann Financial ServicesLower Price TargetBuy -> Buy$9.00 -> $6.50HighView Rating Details
9/12/2017Robert W. BairdReiterated RatingNeutral$5.00 -> $4.00HighView Rating Details
8/9/2017Maxim GroupSet Price TargetBuy$5.00 -> $7.00HighView Rating Details
5/18/2017Leerink SwannUpgradeMarket Perform -> Outperform$4.00 -> $6.00HighView Rating Details
4/26/2017Jefferies Group LLCReiterated RatingHoldLowView Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00N/AView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00N/AView Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00N/AView Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Achillion Pharmaceuticals (NASDAQ:ACHN)

Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Earnings History by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/1/2017Q3 2017($0.18)($0.14)ViewN/AView Earnings Details
8/8/2017Q2 2017($0.16)($0.16)ViewListenView Earnings Details
5/4/2017Q1 2017($0.16)($0.15)ViewN/AView Earnings Details
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.19)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.17)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
2017 EPS Consensus Estimate: ($0.68)
2018 EPS Consensus Estimate: ($0.79)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.17)($0.16)($0.17)
Q2 20173($0.17)($0.17)($0.17)
Q3 20173($0.18)($0.18)($0.18)
Q4 20173($0.19)($0.15)($0.17)
Q1 20181($0.17)($0.17)($0.17)
Q2 20181($0.19)($0.19)($0.19)
Q3 20181($0.21)($0.21)($0.21)
Q4 20181($0.22)($0.22)($0.22)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Achillion Pharmaceuticals (NASDAQ ACHN)

Insider Ownership Percentage: 7.24%
Institutional Ownership Percentage: 75.70%
Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)
Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Insider Trades by Quarter for Achillion Pharmaceuticals (NASDAQ ACHN)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.00View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.00View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.00View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achillion Pharmaceuticals (NASDAQ ACHN)

Source:
DateHeadline
Head-To-Head Contrast: Achillion Pharmaceuticals (ACHN) & The CompetitionHead-To-Head Contrast: Achillion Pharmaceuticals (ACHN) & The Competition
www.americanbankingnews.com - November 20 at 11:19 AM
Achillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - November 19 at 7:56 AM
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% TodayHere's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
finance.yahoo.com - November 16 at 8:41 PM
First Week Of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)First Week Of June 2018 Options Trading For Achillion Pharmaceuticals (ACHN)
www.thestreet.com - November 16 at 3:37 PM
Achillion Pharma (ACHN) Prices 18.37M Share Common Secondary Offering by Johnson & Johnson (JNJ) at $2.75/ShAchillion Pharma (ACHN) Prices 18.37M Share Common Secondary Offering by Johnson & Johnson (JNJ) at $2.75/Sh
www.streetinsider.com - November 16 at 3:37 PM
Pre-Market Most Active for Nov 16, 2017 : ACHN, TVIX, BBY, CSCO, WMT, HMC, ROKU, BAC, GE, NOK, QQQ, AAPL - NasdaqPre-Market Most Active for Nov 16, 2017 : ACHN, TVIX, BBY, CSCO, WMT, HMC, ROKU, BAC, GE, NOK, QQQ, AAPL - Nasdaq
www.nasdaq.com - November 16 at 10:38 AM
Achillion Announces Pricing of Secondary Offering Of Common Stock - GlobeNewswire (press release)Achillion Announces Pricing of Secondary Offering Of Common Stock - GlobeNewswire (press release)
globenewswire.com - November 16 at 10:38 AM
Biotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with BayerBiotech Stock Roundup: Dynavax Vaccine Gets FDA Nod, Loxo Inks Deal with Bayer
finance.yahoo.com - November 16 at 10:38 AM
Achillion Heel: Stock Plunges as J&J ExitsAchillion Heel: Stock Plunges as J&J Exits
finance.yahoo.com - November 16 at 10:38 AM
Achillion (ACHN) Shares Down as J&J Announces Stake SaleAchillion (ACHN) Shares Down as J&J Announces Stake Sale
finance.yahoo.com - November 16 at 10:38 AM
Why Achillion Pharmaceuticals Stock Is Falling TodayWhy Achillion Pharmaceuticals Stock Is Falling Today
finance.yahoo.com - November 16 at 10:38 AM
Achillion Announces Pricing of Secondary Offering Of Common StockAchillion Announces Pricing of Secondary Offering Of Common Stock
finance.yahoo.com - November 16 at 10:38 AM
Today’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia PharmaceuticalsToday’s Research Reports on Trending Tickers: Achillion Pharmaceuticals and Aurinia Pharmaceuticals
finance.yahoo.com - November 16 at 10:38 AM
-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter-$0.15 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - November 15 at 5:26 AM
After-Hours Stock Movers 11/14: (SORL) (CARG) (AAOI) Higher; (ACHN) (MTSI) (SITO) Lower (more...) - StreetInsider.comAfter-Hours Stock Movers 11/14: (SORL) (CARG) (AAOI) Higher; (ACHN) (MTSI) (SITO) Lower (more...) - StreetInsider.com
www.streetinsider.com - November 14 at 8:57 PM
Achillion Pharma (ACHN) Announces Prelim. Proof-of-Concept With ACH-4471 for Treatment of C3G - StreetInsider.comAchillion Pharma (ACHN) Announces Prelim. Proof-of-Concept With ACH-4471 for Treatment of C3G - StreetInsider.com
www.streetinsider.com - November 14 at 8:57 PM
Achillion Pharma (ACHN) Announces 18.37M Secondary Offering of Common Stock - StreetInsider.comAchillion Pharma (ACHN) Announces 18.37M Secondary Offering of Common Stock - StreetInsider.com
www.streetinsider.com - November 14 at 8:57 PM
Achillion shares drop as J&J to sell large stakeAchillion shares drop as J&J to sell large stake
finance.yahoo.com - November 14 at 8:57 PM
Theravance (TBPH) Submits NDA for COPD Candidate RevefenacinTheravance (TBPH) Submits NDA for COPD Candidate Revefenacin
finance.yahoo.com - November 14 at 8:57 PM
Glaxo's Subcutaneous Formulation of Benlysta Approved in EUGlaxo's Subcutaneous Formulation of Benlysta Approved in EU
finance.yahoo.com - November 14 at 3:55 PM
Achillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation ... - StreetInsider.comAchillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation ... - StreetInsider.com
www.streetinsider.com - November 7 at 4:52 PM
Achillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation in the European Union for ACH-4471Achillion Pharma (ACHN) Secures FDA Orphan Drug Designation and Positive Opinion for Orphan Drug Designation in the European Union for ACH-4471
www.streetinsider.com - November 6 at 4:09 PM
Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal HemoglobinuriaAchillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
finance.yahoo.com - November 6 at 4:09 PM
Achillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Buy" at Zacks Investment ResearchAchillion Pharmaceuticals, Inc. (ACHN) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - November 6 at 8:08 AM
FY2017 Earnings Forecast for Achillion Pharmaceuticals, Inc. Issued By Leerink Swann (ACHN)FY2017 Earnings Forecast for Achillion Pharmaceuticals, Inc. Issued By Leerink Swann (ACHN)
www.americanbankingnews.com - November 6 at 8:06 AM
Equities Analysts Offer Predictions for Achillion Pharmaceuticals, Inc.s FY2017 Earnings (ACHN)Equities Analysts Offer Predictions for Achillion Pharmaceuticals, Inc.'s FY2017 Earnings (ACHN)
www.americanbankingnews.com - November 6 at 8:06 AM
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus - NasdaqAchillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus - Nasdaq
www.nasdaq.com - November 4 at 1:23 AM
Achillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in FocusAchillion (ACHN) Q3 Loss Narrows, Pipeline Expansion in Focus
finance.yahoo.com - November 3 at 3:17 PM
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs - GlobeNewswire (press release)Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs - GlobeNewswire (press release)
globenewswire.com - November 1 at 8:41 PM
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical ProgramsAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
finance.yahoo.com - November 1 at 8:41 PM
Achillion reports 3Q lossAchillion reports 3Q loss
finance.yahoo.com - November 1 at 8:41 PM
Achillion Pharmaceuticals, Inc. (ACHN) Issues  Earnings Results, Beats Expectations By $0.03 EPSAchillion Pharmaceuticals, Inc. (ACHN) Issues Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - November 1 at 5:28 PM
Has Achillion Pharmaceuticals Inc (ACHN) Got Enough Cash To Cover Its Short-Term Obligations?Has Achillion Pharmaceuticals Inc (ACHN) Got Enough Cash To Cover Its Short-Term Obligations?
finance.yahoo.com - November 1 at 3:38 PM
Commit To Buy Achillion Pharmaceuticals At $3, Earn 12.9% Annualized Using OptionsCommit To Buy Achillion Pharmaceuticals At $3, Earn 12.9% Annualized Using Options
www.nasdaq.com - October 26 at 3:13 PM
Achillion Pharma (ACHN) Granted Composition of Matter Patent by USTPO for ACH-4471Achillion Pharma (ACHN) Granted Composition of Matter Patent by USTPO for ACH-4471
www.streetinsider.com - October 25 at 4:15 PM
Zacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.18 EPSZacks: Brokerages Expect Achillion Pharmaceuticals, Inc. (ACHN) to Post -$0.18 EPS
www.americanbankingnews.com - October 25 at 4:12 PM
Achillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by BrokeragesAchillion Pharmaceuticals, Inc. (ACHN) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 8:45 AM
Achillion Pharmaceuticals, Inc. (ACHN) Set to Announce Earnings on WednesdayAchillion Pharmaceuticals, Inc. (ACHN) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 25 at 6:04 AM
Achillion Pharma (ACHN) Granted Composition of Matter Patent by USTPO for ACH-4471 - StreetInsider.comAchillion Pharma (ACHN) Granted Composition of Matter Patent by USTPO for ACH-4471 - StreetInsider.com
www.streetinsider.com - October 24 at 8:27 PM
Achillion Pharma (ACHN) Announces Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at AASLDAchillion Pharma (ACHN) Announces Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at AASLD
www.streetinsider.com - October 24 at 3:25 PM
Achillion Pharma (ACHN) Announces Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir ... - StreetInsider.comAchillion Pharma (ACHN) Announces Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir ... - StreetInsider.com
www.streetinsider.com - October 23 at 3:44 PM
Achillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver MeetingAchillion Announces Presentation of Data From OMEGA-1 Phase 2b Trial With Odalasvir, AL-335, and Simeprevir (JNJ-4178) at the 2017 Liver Meeting
finance.yahoo.com - October 23 at 3:44 PM
Johnson & Johnson Shuts Insulin Pump Business, Inks Other DealsJohnson & Johnson Shuts Insulin Pump Business, Inks Other Deals
www.thestreet.com - October 20 at 8:38 PM
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : October 18, 2017Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : October 18, 2017
finance.yahoo.com - October 18 at 3:52 PM
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : October 17, 2017Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : ACHN-US : October 17, 2017
finance.yahoo.com - October 17 at 3:40 PM
-$0.18 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter-$0.18 EPS Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - October 6 at 6:26 PM
Achillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by AnalystsAchillion Pharmaceuticals, Inc. (ACHN) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - September 30 at 8:52 AM
Achillion to Present at the 2017 Leerink Partners Rare Disease Roundtable SeriesAchillion to Present at the 2017 Leerink Partners Rare Disease Roundtable Series
feeds.benzinga.com - September 20 at 6:55 AM
Achillion Pharmaceuticals, Inc. (ACHN) Given Neutral Rating at Chardan CapitalAchillion Pharmaceuticals, Inc. (ACHN) Given Neutral Rating at Chardan Capital
www.americanbankingnews.com - September 20 at 6:26 AM
-$0.18 Earnings Per Share Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter-$0.18 Earnings Per Share Expected for Achillion Pharmaceuticals, Inc. (ACHN) This Quarter
www.americanbankingnews.com - September 18 at 12:28 AM

Social Media

Financials

Chart

Achillion Pharmaceuticals (NASDAQ ACHN) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.